文献速递临床试验与 GCP医学教育与科研方法

英国药品和医疗产品监管局「临床试验立法改革提案咨询」:试验方法学研究伙伴关系适应性设计工作组的回应,聚焦数据共享

Medicines and Healthcare products Regulatory Agency's "Consultation on proposals for legislative changes for clinical trials": a response from the Trials Methodology Research Partnership Adaptive Designs Working Group, with a focus on data sharing.
PubMed 文献 · Trials · 2023-10-05

英国药品和医疗产品监管局就完善临床试验立法提案开展咨询,试验方法学研究伙伴关系适应性设计工作组结合成员讨论指出,提案过度依赖立法改变实践,可能对异质性更高的适应性设计试验造成更大负面影响,且提案与咨询完全未涉及数据共享;工作组强烈建议数据共享应成为常态而非例外。

要点

  • 工作组认为提案过度依赖立法改变实践,部分试验将难以完全合规。
  • 适应性设计试验异质性更高、挑战更多,立法增加可能对其负面影响更大。
  • 提案与咨询完全未涉及数据共享,工作组强烈建议数据共享应成为常态。

核心结论

  • 工作组对引入立法能否实现预期结果持怀疑态度(部分例外),并强烈建议数据共享应成为常态而非例外。

研究设计与样本

  • 本文为试验方法学研究伙伴关系适应性设计工作组对英国药品和医疗产品监管局临床试验立法改革提案咨询的回应文章,工作组由医学研究理事会与国家卫生与照护研究所共同资助。

主要发现

  • 工作组认为提案过度依赖立法改变实践,而临床试验具有异质性,部分试验将难以完全合规。
  • 适应性设计临床试验比非适应性设计异质性更高、面临更多挑战,立法增加可能对适应性设计产生更大负面影响。
  • 数据共享——将匿名个体层面临床试验数据提供给其他研究者进一步使用——在提案和整个咨询中完全缺失。
  • 数据共享的益处包括加速创新、改善药物安全性和有效性监测、减少受试者暴露于不必要风险。
  • 英国已有讨论和鼓励数据共享的文件,例如《开放研究数据公约》和医学研究理事会的数据共享政策。

临床怎么用

  • 原文未据此给出临床推荐;工作组在回应中强烈建议数据共享应成为常态而非例外,并希望即将出台的临床试验提案能就此重要议题邀请讨论。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the UK, the Medicines and Healthcare products Regulatory Agency consulted on proposals "to improve and strengthen the UK clinical trials legislation to help us make the UK the best place to research and develop safe and innovative medicines". The purpose of the consultation was to help finalise the proposals and contribute to the drafting of secondary legislation. We discussed these proposals as members of the Trials Methodology Research Partnership Adaptive Designs Working Group, which is jointly funded by the Medical Research Council and the National Institute for Health and Care Research. Two topics arose frequently in the discussion: the emphasis on legislation, and the absence of questions on data sharing. It is our opinion that the proposals rely heavily on legislation to change practice. However, clinical trials are heterogeneous, and as a result some trials will struggle to comply with all of the proposed legislation. Furthermore, adaptive design clinical trials are even more heterogeneous than their non-adaptive counterparts, and face more challenges. Consequently, it is possible that increased legislation could have a greater negative impact on adaptive designs than non-adaptive designs. Overall, we are sceptical that the introduction of legislation will achieve the desired outcomes, with some exceptions. Meanwhile the topic of data sharing - making anonymised individual-level clinical trial data available to other investigators for further use - is entirely absent from the proposals and the consultation in general. However, as an aspect of the wider concept of open science and reproducible research, data sharing is an increasingly important aspect of clinical trials. The benefits of data sharing include faster innovation, improved surveillance of drug safety and effectiveness and decreasing participant exposure to unnecessary risk. There are already a number of UK-focused documents that discuss and encourage data sharing, for example, the Concordat on Open Research Data and the Medical Research Council's Data Sharing Policy. We strongly suggest that data sharing should be the norm rather than the exception, and hope that the forthcoming proposals on clinical trials invite discussion on this important topic.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Law M, Couturier DL, Choodari-Oskooei B, et al. Medicines and Healthcare products Regulatory Agency's "Consultation on proposals for legislative changes for clinical trials": a response from the Trials Methodology Research Partnership Adaptive Designs Working Group, with a focus on data sharing. Trials. 2023. PMID: 37798805. doi:10.1186/s13063-023-07576-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。